What Expanded CVD Medicare Coverage May Mean for Novo Nordisk’s Wegovy

A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, but analysts remain dubious of the estimate.

Scroll to Top